NASDAQ:IFRX

InflaRx (IFRX) Stock Forecast, Price & News

$4.15

-0.06 (-1.43%)

(As of 06/5/2023 ET)

Compare

Today's Range: $4.11
▼
$4.26
50-Day Range: $1.78
▼
$6.10
52-Week Range: $0.78
▼
$7.25

Volume: 183,196 shs
Average Volume: 345,001 shs
Market Capitalization: $185.51 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.00

InflaRx MarketRank™ Forecast

Analyst Rating: Buy
3.20 Rating Score
Upside/Downside: 237.3% Upside
$14.00 Price Target
Short Interest: Healthy
1.58% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.26) to ($0.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

534th out of 985 stocks

Pharmaceutical Preparations Industry

261st out of 483 stocks

3.6

Analyst's Opinion

Consensus Rating
InflaRx has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.00, InflaRx has a forecasted upside of 237.3% from its current price of $4.15.
Amount of Analyst Coverage
InflaRx has only been the subject of 4 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.58% of the outstanding shares of InflaRx have been sold short.
Short Interest Ratio / Days to Cover
InflaRx has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in InflaRx has recently decreased by 26.28%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
InflaRx does not currently pay a dividend.
Dividend Growth
InflaRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IFRX.

0.0

News and Social Media Coverage

Search Interest
Only 4 people have searched for IFRX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added InflaRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -94% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, InflaRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 9.04% of the stock of InflaRx is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for InflaRx are expected to grow in the coming year, from ($1.26) to ($0.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of InflaRx is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of InflaRx is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
InflaRx has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About InflaRx (NASDAQ:IFRX) Stock

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

IFRX Stock News Headlines

May 22, 2023 | americanbankingnews.com

InflaRx (NASDAQ:IFRX) vs. Viveon Health Acquisition (NYSE:VHAQ) Head to Head Contrast

May 15, 2023 | markets.businessinsider.com

SVB Securities Reaffirms Their Buy Rating on InflaRx (IFRX)

June 6, 2023 | Behind the Markets (Ad)

"Unknown laser company making HUGE profit from Russia-Ukraine War"

On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>

May 12, 2023 | markets.businessinsider.com

Raymond James Remains a Buy on InflaRx (IFRX)

May 12, 2023 | msn.com

Raymond James Maintains InflaRx N.V. (IFRX) Strong Buy Recommendation

May 12, 2023 | msn.com

HC Wainwright & Co. Reiterates InflaRx N.V. (IFRX) Buy Recommendation

May 11, 2023 | finanznachrichten.de

InflaRx N.V.: InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

May 11, 2023 | finance.yahoo.com

InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

June 6, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 11, 2023 | markets.businessinsider.com

LifeSci Capital Reaffirms Their Buy Rating on InflaRx (IFRX)

May 3, 2023 | finance.yahoo.com

InflaRx N.V.'s (NASDAQ:IFRX) Profit Outlook

April 22, 2023 | americanbankingnews.com

InflaRx (NASDAQ:IFRX) PT Lowered to $9.00 at HC Wainwright

April 18, 2023 | finance.yahoo.com

InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million

April 15, 2023 | finanznachrichten.de

InflaRx N.V.: InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

April 14, 2023 | finance.yahoo.com

InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

April 12, 2023 | finanznachrichten.de

InflaRx N.V.: InflaRx Announces Public Offering of Ordinary Shares

April 12, 2023 | finanznachrichten.de

InflaRx N.V.: InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares

April 12, 2023 | finance.yahoo.com

InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares

April 11, 2023 | finance.yahoo.com

InflaRx Announces Public Offering of Ordinary Shares

April 8, 2023 | americanbankingnews.com

InflaRx (NASDAQ:IFRX) Price Target Raised to $10.00 at HC Wainwright

April 8, 2023 | americanbankingnews.com

InflaRx (NASDAQ:IFRX) Given New $25.00 Price Target at Raymond James

April 7, 2023 | americanbankingnews.com

InflaRx (NASDAQ:IFRX) Stock Rating Upgraded by Guggenheim

April 7, 2023 | americanbankingnews.com

Stock Traders Buy High Volume of InflaRx Call Options (NASDAQ:IFRX)

April 6, 2023 | americanbankingnews.com

InflaRx (NASDAQ:IFRX) Upgraded by Lifesci Capital to "Outperform"

April 5, 2023 | finance.yahoo.com

InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment

April 5, 2023 | finance.yahoo.com

Why Shares of InflaRx Are Soaring Wednesday

April 5, 2023 | investorplace.com

InflaRx (IFRX) Stock Pops as FDA Grants Emergency Use Authorization

See More Headlines

IFRX Price History

30 days | 90 days | 365 days | Advanced Chart

IFRX Company Calendar

Last Earnings: 5/11/2023
Today: 6/06/2023
Next Earnings (Estimated): 8/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IFRX
CUSIP: N/A
CIK: 1708688
Web: www.inflarx.de
Phone: 493641508180
Fax: N/A
Employees: 55
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $14.00
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +237.3%
Consensus Rating: Buy
Rating Score (0-4): 3.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,070,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -28.56%
Return on Assets: -25.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.24
Quick Ratio: 11.24

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.08 per share
Price / Book: 2.00

Miscellaneous

Outstanding Shares: 44,700,000
Free Float: 37,417,000
Market Cap: $185.51 million
Optionable: Not Optionable
Beta: 0.97

Key Executives

Niels Christoph Riedemann
Chief Executive Officer & Executive Director

Thomas Taapken
Chief Financial Officer

Renfeng Guo
Executive Director & Chief Scientific Officer

Maria Habel
VP, Head-Pre-Clinical Research & Development

Bruce P. Burnett
Vice President & Head-Medical Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IFRX Stock - Frequently Asked Questions

Should I buy or sell InflaRx stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IFRX shares.
View IFRX analyst ratings or view top-rated stocks.
What is InflaRx's stock price forecast for 2023?: 5 equities research analysts have issued 12-month price targets for InflaRx's shares. Their IFRX share price forecasts range from $8.00 to $25.00. On average, they expect the company's share price to reach $14.00 in the next year. This suggests a possible upside of 237.3% from the stock's current price.
View analysts price targets for IFRX or view top-rated stocks among Wall Street analysts.
How have IFRX shares performed in 2023?: InflaRx's stock was trading at $3.10 at the beginning of the year. Since then, IFRX stock has increased by 33.9% and is now trading at $4.15.
View the best growth stocks for 2023 here.
Are investors shorting InflaRx?: InflaRx saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 705,400 shares, a decline of 26.3% from the April 30th total of 956,900 shares. Based on an average daily volume of 2,410,000 shares, the short-interest ratio is presently 0.3 days.
View InflaRx's Short Interest.
When is InflaRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our IFRX earnings forecast.
How were InflaRx's earnings last quarter?: InflaRx (NASDAQ:IFRX) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03.
What ETF holds InflaRx's stock ?: Invesco Raymond James SB-1 Equity ETF holds 63,995 shares of IFRX stock, representing 0.23% of its portfolio.

What other stocks do shareholders of InflaRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Kadmon (KDMN) and Moderna (MRNA).
When did InflaRx IPO?: (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
What is InflaRx's stock symbol?: InflaRx trades on the NASDAQ under the ticker symbol "IFRX."
Who are InflaRx's major shareholders?: InflaRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Raymond James Financial Services Advisors Inc. (0.35%), Susquehanna International Group LLP (0.24%), Commonwealth Equity Services LLC (0.20%), JPMorgan Chase & Co. (0.16%) and Raymond James & Associates (0.13%).
How do I buy shares of InflaRx?: Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is InflaRx's stock price today?: One share of IFRX stock can currently be purchased for approximately $4.15.
How much money does InflaRx make?: InflaRx (NASDAQ:IFRX) has a market capitalization of $185.51 million. The company earns $-31,070,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.
How can I contact InflaRx?: InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The official website for the company is www.inflarx.de. The company can be reached via phone at 493641508180 or via email at jordan.zwick@inflarx.de.

This page (NASDAQ:IFRX) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial